The genomics of heart failure : design and rationale of the HERMES consortium
(2021) In ESC Heart Failure 8(6). p.5531-5541- Abstract
Aims: The HERMES (HEart failure Molecular Epidemiology for Therapeutic targetS) consortium aims to identify the genomic and molecular basis of heart failure. Methods and results: The consortium currently includes 51 studies from 11 countries, including 68 157 heart failure cases and 949 888 controls, with data on heart failure events and prognosis. All studies collected biological samples and performed genome-wide genotyping of common genetic variants. The enrolment of subjects into participating studies ranged from 1948 to the present day, and the median follow-up following heart failure diagnosis ranged from 2 to 116 months. Forty-nine of 51 individual studies enrolled participants of both sexes; in these studies, participants with... (More)
Aims: The HERMES (HEart failure Molecular Epidemiology for Therapeutic targetS) consortium aims to identify the genomic and molecular basis of heart failure. Methods and results: The consortium currently includes 51 studies from 11 countries, including 68 157 heart failure cases and 949 888 controls, with data on heart failure events and prognosis. All studies collected biological samples and performed genome-wide genotyping of common genetic variants. The enrolment of subjects into participating studies ranged from 1948 to the present day, and the median follow-up following heart failure diagnosis ranged from 2 to 116 months. Forty-nine of 51 individual studies enrolled participants of both sexes; in these studies, participants with heart failure were predominantly male (34–90%). The mean age at diagnosis or ascertainment across all studies ranged from 54 to 84 years. Based on the aggregate sample, we estimated 80% power to genetic variant associations with risk of heart failure with an odds ratio of ≥1.10 for common variants (allele frequency ≥ 0.05) and ≥1.20 for low-frequency variants (allele frequency 0.01–0.05) at P < 5 × 10−8 under an additive genetic model. Conclusions: HERMES is a global collaboration aiming to (i) identify the genetic determinants of heart failure; (ii) generate insights into the causal pathways leading to heart failure and enable genetic approaches to target prioritization; and (iii) develop genomic tools for disease stratification and risk prediction.
(Less)
- author
- author collaboration
- organization
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Association studies, Biomarkers, Cardiomyopathy, Genetics, Heart failure
- in
- ESC Heart Failure
- volume
- 8
- issue
- 6
- pages
- 5531 - 5541
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- scopus:85114632006
- pmid:34480422
- ISSN
- 2055-5822
- DOI
- 10.1002/ehf2.13517
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
- id
- 469618eb-613c-479c-b61a-126e0fbf7994
- date added to LUP
- 2021-10-18 11:00:44
- date last changed
- 2024-12-29 14:49:13
@article{469618eb-613c-479c-b61a-126e0fbf7994, abstract = {{<p>Aims: The HERMES (HEart failure Molecular Epidemiology for Therapeutic targetS) consortium aims to identify the genomic and molecular basis of heart failure. Methods and results: The consortium currently includes 51 studies from 11 countries, including 68 157 heart failure cases and 949 888 controls, with data on heart failure events and prognosis. All studies collected biological samples and performed genome-wide genotyping of common genetic variants. The enrolment of subjects into participating studies ranged from 1948 to the present day, and the median follow-up following heart failure diagnosis ranged from 2 to 116 months. Forty-nine of 51 individual studies enrolled participants of both sexes; in these studies, participants with heart failure were predominantly male (34–90%). The mean age at diagnosis or ascertainment across all studies ranged from 54 to 84 years. Based on the aggregate sample, we estimated 80% power to genetic variant associations with risk of heart failure with an odds ratio of ≥1.10 for common variants (allele frequency ≥ 0.05) and ≥1.20 for low-frequency variants (allele frequency 0.01–0.05) at P < 5 × 10<sup>−8</sup> under an additive genetic model. Conclusions: HERMES is a global collaboration aiming to (i) identify the genetic determinants of heart failure; (ii) generate insights into the causal pathways leading to heart failure and enable genetic approaches to target prioritization; and (iii) develop genomic tools for disease stratification and risk prediction.</p>}}, author = {{Lumbers, R. Thomas and Shah, Sonia and Lin, Honghuang and Czuba, Tomasz and Henry, Albert and Swerdlow, Daniel I. and Mälarstig, Anders and Andersson, Charlotte and Verweij, Niek and Holmes, Michael V. and Ärnlöv, Johan and Svensson, Per and Hemingway, Harry and Sallah, Neneh and Almgren, Peter and Aragam, Krishna G. and Asselin, Geraldine and Backman, Joshua D. and Biggs, Mary L. and Bloom, Heather L. and Boersma, Eric and Brandimarto, Jeffrey and Brown, Michael R. and Brunner-La Rocca, Hans Peter and Carey, David J. and Chaffin, Mark D. and Chasman, Daniel I. and Chazara, Olympe and Chen, Xing and Chen, Xu and Chung, Jonathan H. and Chutkow, William and Cleland, John G.F. and Cook, James P. and de Denus, Simon and Dehghan, Abbas and Delgado, Graciela E. and Denaxas, Spiros and Doney, Alexander S. and Dörr, Marcus and Dudley, Samuel C. and Engström, Gunnar and Esko, Tõnu and Fatemifar, Ghazaleh and Felix, Stephan B. and Finan, Chris and Ford, Ian and Lindgren, Cecilia M. and Melander, Olle and Perola, Markus}}, issn = {{2055-5822}}, keywords = {{Association studies; Biomarkers; Cardiomyopathy; Genetics; Heart failure}}, language = {{eng}}, number = {{6}}, pages = {{5531--5541}}, publisher = {{John Wiley & Sons Inc.}}, series = {{ESC Heart Failure}}, title = {{The genomics of heart failure : design and rationale of the HERMES consortium}}, url = {{http://dx.doi.org/10.1002/ehf2.13517}}, doi = {{10.1002/ehf2.13517}}, volume = {{8}}, year = {{2021}}, }